Get started
Author

Sarah Hersey

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
2021 · Grzegorz S. Nowakowski, Annalisa Chiappella, et al. · Journal of Clinical Oncology · 275
PDF
Biological impact of iberdomide in patients with active systemic lupus erythematosus
2022 · Peter E Lipsky, Ronald van Vollenhoven, et al. · Annals of the Rheumatic Diseases · 35
PDF
Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels
2022 · Lizhi Yu, Gonzalo Lopez, et al. · PLoS ONE · 26
PDF
2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry ( Part 2 – Recommendations on Biomarkers/CDx Assays Development & Validation, Cytometry Validation & Innovation, Biotherapeutics PK LBA Regulated Bioanalysis, Critical Reagents & Positive Controls Generation)
2022 · Sarah Hersey, Steve Keller, et al. · Bioanalysis · 25
PDF
Reviews Preclinical Safety and Immune-Modulating Effects of Therapeutic Monoclonal Antibodies to Interleukin-6 and Tumor Necrosis Factor-α in Cynomolgus Macaques
2005 · Pauline L. Martin, Joel Cornacoff, et al. · Journal of Immunotoxicology · 20
PDF
2023 White Paper on Recent Issues in Bioanalysis: EU IVDR 2017/746 Implementation/Impact, IVD/CDx/CLIA Approved Assays, High Dimensional Cytometry, Multiplexing Technologies, LBA Tissue Analysis, Vaccine Study Endpoints, Cell-Based Assays for Biomarkers, Cell Therapy and Vaccines ( PART 2 – Recommendations on Development & Validation of Biomarkers, IVD, CDx, Cell-Based, Flow Cytometry, Ligand-Binding and Enzyme Assays; Advanced Critical Reagents Strategies)
2024 · Olga Kholmanskikh, Yow-Ming Wang, et al. · Bioanalysis · 19
PDF
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium
2025 · Michael Boyiadzis, Andrew H. Wei, et al. · Cancer · 11
Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Images
2026 · Brittany McKelvey, Pedro A. Torres-Saavedra, et al. · Modern Pathology · 8
Urinary Proteomics and Outcomes in Heart Failure With Preserved Ejection Fraction
2024 · Corinne Carland, Lei Zhao, et al. · Journal of the American Heart Association · 7
PDF
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics
2023 · Miriam Meyer, Andrea Mahr, et al. · Nature Reviews Drug Discovery · 6
A Novel BCMA Immunohistochemistry Assay Reveals a Heterogenous and Dynamic BCMA Expression Profile in Multiple Myeloma
2023 · Mingjun Zhang, Falon Gray, et al. · Modern Pathology · 5
2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A – Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B – Regulatory Agencies’ Input on Biomarkers, IVD/CDx and Biomarker Assay Validation (BAV))
2025 · Sarah Hersey, Kristina McGuire, et al. · Bioanalysis · 4
PDF
Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models
2019 · Patrick R. Hagner, Michelle Waldman, et al. · Blood · 4
Abstract P2-02-18: Agreement Across 10 Artificial Intelligence Models in Assessing HER2 in Breast Cancer Whole Slide Images: Findings from the Friends of Cancer Research Digital PATH Project
2025 · Brittany McKelvey, Pedro A. Torres-Saavedra, et al. · Clinical Cancer Research · 1
LBA-12 Iberdomide, Daratumumab, Dexamethasone (IberDd) vs Daratumumab, Bortezomib, Dexamethasone (DVd) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From EXCALIBER-RRMM Phase 3 Study
2026 · Sagar Lonial, Meletios A. Dimopoulos, et al. · Clinical Lymphoma Myeloma & Leukemia
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
2026 · Sagar Lonial, Meletios A Dimopoulos, et al. · The Lancet Oncology
Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe
2026 · Sarah Hersey, Haydar Celik, et al. · European Journal of Cancer
Toward a harmonized assessment of MRD by NGS: blinded pilot study of NGS assays by MPAACT consortium
2026 · Vanessa Obourn, Shalaka Patel, et al. · Figshare
Toward a harmonized assessment of MRD by NGS: blinded pilot study of NGS assays by MPAACT consortium
2026 · Vanessa Obourn, Shalaka Patel, et al. · Personalized Medicine
Development of a multi-biomarker risk score based on serum proteins by the Prognostic Lung Fibrosis Consortium (PROLIFIC)
2024 · Peter Schafer, John Rassa, et al.
Urinary Proteins Levels Associated With Outcomes in Heart Failure With Preserved Ejection Fraction
2023 · Corinne Carland, Lei Zhao, et al. · Journal of the American College of Cardiology
Works count: 21
Citation count: 446
H-index: 8
I10-index: 7
Year
Topic
Type